



HESI CARDIAC SAFETY COMMITTEE

FALL 2022 NEWSLETTER



2023 ANNUAL CARDIAC COMMITTEE MEETING

As the Steering Team are preparing plans for our Annual Committee Meeting in 2023, we would like your input! Please complete this brief 4 question survey to provide your thoughts on virtual vs in-person and keynote topics by Monday, December 5th. Link - [here](#)

SOT ABSTRACTS - DEADLINE DECEMBER 1

A friendly reminder that the Society of Toxicology has extended the abstract submission for the 2023 meeting until December 1. See more online [here](#). Working Groups are encouraged to consider submitting an abstract to share recent work! Please contact

POSTER PRESENTATIONS AT THE 2022 SAFETY PHARMACOLOGY SOCIETY MEETING:

At the recent SPS Meeting, we are proud that our committee presented three posters, highlighted below. Please reach out to HESI Staff if you would like more information on the respective projects or a PDF copy. SPS members can visit the [meeting page - link here](#) via the Attendee Hub.

- JTpeak Assessment In Ambulatory Dog And Monkey An Update From The HESI Working Group
- Assessment of chronic drug treatment induced cardiotoxicity a project of the HESI Stem Cell Working Group
- Biomarker-Based In Vitro Evaluation of Chronic Drug Treatment-Induced Cardiotoxicity: A HESI Stem Cell Working Group Project

NEW AND ONGOING CARDIAC COMMITTEE RESEARCH



Blood Pressure Study – The Integrative Strategies Workgroup has launched a pilot study this fall to assess changes in Blood Pressure in the canine in vivo cardiovascular model using telemetry recording methods to detect positive and negative effects as a result of drug exposures for compounds with known BP effects in the clinic. The full study has several organizations signed up already, however, seek additional sites if interested in joining the efforts. The pilot group plans to present their findings to the workgroup in December.

Biomarkers POC3 – The Biomarkers Workgroup is in works for starting a proof-of-concept 3 (POC3) study TBD in Q1 2023. The POC3 study aims to establish predictors of thrombotic complications and translational biomarkers of incipient thrombosis. The study objectives are to induce hemostatic imbalance with defined stimuli in a rat model using both a procoagulant agent, such as a thromboplastin and tissue factor reagent, Neoplastine CI-plus and an antifibrinolytic agent, using tranexamic acid. The goal is to characterize the prothrombotic phenotype with refined set of biomarkers for hypercoagulability & hypofibrinolysis, as well as use this model to identify novel markers, pathways & assays suitable for early preclinical test pipeline. The group conducted two pilot studies for both Tissue Factor and Tranexamic Acid and the group aims to present to the larger committee later this Fall to present the pilot results and have a call for partners – stay tuned!

The **Stem Cell Working Group** completed data collection for a chronic cardiotoxic study and are working on the data analysis and publication. This large study resulted in 49 datasets from 22 sites across the globe. A data analyst is working with the team to organize, QC and evaluate results.

ICH Q&AS TRAINING STILL AVAILABLE!

HESI and SPS developed an on-demand training opportunity based on the live event held this past June: A closer look at the new ICH E14/S7b Q&A's and Training Materials. The on-demand content is still available to access. Learn more here and ask about the HESI member discount! [link here](#)

Early Career Webinar series – We are once again awarding postdoctoral or Early Career Researchers working in cardiovascular safety science or a related field for our 2023 Early Career Seminar Award Series. This award offers an opportunity to share your research, learn from and network with experts in the toxicology and safety pharmacology fields from academia, regulatory agencies and pharmaceutical companies. The application deadline was Nov 21st – once the Steering Team review all candidates, the awardees will be announced in December with webinars beginning in early 2023.

Last years' awardees included:

[Dr. Julia Hotek, Merck - link here](#)

[Dr. Arvin Soepriatna, Brown University - link here](#)

[Dr. Shagun Krishna, NTP-NIEHS - link here](#)

HESI NEWS

Don't miss out on the following application deadlines! Reach out to HESI Staff for more information.

HESI Innovation Prize: The 2022-2023 HESI Innovation Prize will recognize public sector scientists who have helped to reduce disproportionate health burdens in underserved populations and/or to promote greater health equity. The HESI Innovation Prize recognizes exceptional scientists who share HESI's commitment to synthesizing ideas, resources, and collaborators across scientific disciplines and sectors - and who have demonstrated creativity and impact in doing so. Learn more and apply by December 15, 2022 [here](#).



The HESI Emerging Issues Call for Proposals is now open! HESI seeks your suggestions for priority emerging scientific issues (human or environmental health) that should be addressed through a focused, multi-sector, collaborative program. Proposals will be reviewed in early 2023 and one or more may be selected to form a new scientific program within HESI. Proposals are due January 12, 2023. Download the proposal form [here](#).